

Lung Cancer: Small Cell Lung Cancer Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

Pathology: _____ **Stage:** _____

Line of Therapy: Neoadjuvant/Pre-Op Adjuvant/Post-Op
 1st Line 2nd Line 3rd Line 3rd Line+
 Maintenance

ECOG Performance Status: _____ **ICD-10 Code:** _____

Biomarkers/Characteristics: (Select all that apply)

ALK Status: Negative Positive Not Reported

EGFR: Negative Positive Not Reported

BRAF: V600E Mutation V600K Mutation

Wild Type Not Reported

MET Amplification: Negative Positive Not Reported

RET Gene Rearrangement: Absent Present Not Reported

ROS1 Rearrangement: Negative Positive Not Reported

Limited Stage | Primary, Adjuvant, or First Line of Therapy (1st Line)

Carboplatin and etoposide (Toposar) ± XRT

Cisplatin and etoposide (Toposar) ± XRT

Extensive Stage | First Line of Therapy (1st Line)

Carboplatin and etoposide (Toposar)

Second and Subsequent Lines of Therapy (2nd Line+) | Relapse Greater than Six (6) Months

Carboplatin and etoposide (Toposar)

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

